WHY FUNGUS IS YOUR GUT'S BEST FRIEND
DEAD

Serial Number

87504901

Owner

PathoBiome LLC

Attorney

Brian E. Turung

Filing Date

Jun 26, 2017

Add to watchlist:

No watchlists yet
View on USPTO

WHY FUNGUS IS YOUR GUT'S BEST FRIEND Trademark

Serial Number: 87504901

WHY FUNGUS IS YOUR GUT'S BEST FRIEND is a trademark filed by PathoBiome LLC on June 26, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

PathoBiome LLC (23 trademarks)

Suite 4500
Cleveland, OH 44115

Entity Type: 16

BIOHM HEALTH LLC (23 trademarks)

CLEVELAND, OH 44113

Entity Type: 16

Trademark Details

Filing Date

June 26, 2017

Registration Date

Not Registered

Published for Opposition

March 13, 2018

Goods & Services

Educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and how to have and maintain and/or monitor a heathy gastrointestinal tract; educational services, namely, providing online instruction and distribution of educational materials in connection therewith featuring information regarding the gastrointestinal tract and how to have and maintain and/or monitor a heathy large intestine

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; preparations in the nature of a vaginal probiotic for the treatment and/or prevention of bacterial or fungal vaginal infection; nutraceuticals for the treatment and/or prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and/or nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and/or bacterial probiotics, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; diagnostic colon test kit comprised of medical diagnostic reagents and assays for the detection of cancer, polyps, ulcers, inflammation, infection, bacteria and microorganisms; diagnostic colon cancer test kit comprised of medical diagnostic reagents and assays; colorectal cancer screening test kit comprised of medical diagnostic reagents and assays

Medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; medical diagnostic testing services to apprise individuals and/or animals of the status of the gastrointestinal tract; medical diagnostic testing services to apprise individuals and/or animals of the status of the large intestine; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the gastrointestinal tract; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the large intestine

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 9, 2019 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 9, 2019 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 10, 2019 EXRA
SOU EXTENSION 2 GRANTED
May 8, 2019 EX2G
SOU EXTENSION 2 FILED
May 8, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
May 8, 2019 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 30, 2019 ASGN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2018 EXRA
SOU EXTENSION 1 GRANTED
Oct 26, 2018 EX1G
SOU EXTENSION 1 FILED
Oct 26, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 26, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 8, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 13, 2018 NPUB
PUBLISHED FOR OPPOSITION
Mar 13, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 21, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 1, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 1, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 1, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 1, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 1, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 1, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 31, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 2, 2017 GNRN
NON-FINAL ACTION E-MAILED
Aug 2, 2017 GNRT
NON-FINAL ACTION WRITTEN
Aug 2, 2017 CNRT
ASSIGNED TO EXAMINER
Jul 31, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 1, 2017 NWOS